Published in Arterioscler Thromb Vasc Biol on July 26, 2007
Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis (2014) 1.86
Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study. Hum Genet (2008) 1.17
Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study. Atherosclerosis (2008) 0.93
Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J (2011) 0.90
Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature. Tex Heart Inst J (2010) 0.88
Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications. World J Cardiol (2015) 0.87
Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians. J Clin Endocrinol Metab (2010) 0.86
Apo E4 and lipoprotein-associated phospholipase A2 synergistically increase cardiovascular risk. Atherosclerosis (2012) 0.84
Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc Health Risk Manag (2010) 0.83
Lipoprotein-associated phospholipase A2 as a predictive biomarker of sub-clinical inflammation in cardiovascular diseases. Maedica (Buchar) (2010) 0.78
A review of time courses and predictors of lipid changes with fenofibric acid-statin combination. Cardiovasc Drugs Ther (2012) 0.78
Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study. Atherosclerosis (2015) 0.77
High density lipoproteins and type 2 diabetes: Emerging concepts in their relationship. World J Exp Med (2014) 0.77
Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia. J Clin Lipidol (2014) 0.76
The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of apoB/Lp-PLA₂. J Lipid Res (2013) 0.75
Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease. J Am Heart Assoc (2015) 0.75
Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Med (2017) 0.75
Short-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants. Transl Res (2011) 0.75
Lp-PLA2: inflammatory biomarker of vascular risk in multiple sclerosis. J Clin Immunol (2012) 0.75
A review of drug-induced hyponatremia. Am J Kidney Dis (2008) 2.97
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation (2004) 1.91
Therapeutic approach in patients with dysnatraemias. Nephrol Dial Transplant (2006) 1.90
Association of Helicobacter pylori infection with cardiovascular disease--is it just a myth? Eur J Intern Med (2010) 1.67
Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf (2008) 1.58
Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin (2010) 1.56
Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study. Arthritis Res Ther (2006) 1.52
B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res (2006) 1.50
Benign migratory glossitis or geographic tongue: an enigmatic oral lesion. Am J Med (2002) 1.49
Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol (2007) 1.46
Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost (2003) 1.45
New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol (2007) 1.42
Lipoprotein (a) levels and apolipoprotein (a) isoform size in patients with subclinical hypothyroidism: effect of treatment with levothyroxine. Thyroid (2003) 1.40
Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem (2005) 1.40
The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin (2011) 1.39
α-Defensins and hsCRP levels in inflammatory response of standard and laparoendoscopic single-site cholecystectomy. Surg Endosc (2011) 1.38
The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta (2009) 1.26
Gender-related and age-related urinalysis of healthy subjects by NMR-based metabonomics. NMR Biomed (2008) 1.25
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant (2006) 1.24
Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J Am Coll Cardiol (2008) 1.24
A review of drug-induced hypocalcemia. J Bone Miner Metab (2009) 1.23
The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin (2005) 1.22
A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin Cancer Res (2007) 1.22
Apolipoprotein E and renal disease. Am J Kidney Dis (2004) 1.20
Metabolomic signatures of aggressive prostate cancer. Prostate (2013) 1.17
Novel roles of vitamin D in disease: what is new in 2011? Eur J Intern Med (2011) 1.14
LDL cholesterol estimation in patients with the metabolic syndrome. Lipids Health Dis (2006) 1.12
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis (2004) 1.11
Prediabetes: to treat or not to treat? Eur J Pharmacol (2011) 1.11
Oxidized phospholipids are more potent antagonists of lipopolysaccharide than inducers of inflammation. J Immunol (2010) 1.06
Dyslipidemia associated with chronic kidney disease. Open Cardiovasc Med J (2011) 1.06
Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev Cardiol (2006) 1.05
Acute pancreatitis possibly associated with combined salicylate and atorvastatin therapy. JOP (2003) 1.04
The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol (2006) 1.03
Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism (2006) 1.02
Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol (2006) 1.02
B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol Oncol (2007) 1.02
Lp-PLA2: an emerging biomarker of coronary heart disease. Expert Rev Mol Diagn (2002) 1.01
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther (2007) 1.01
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol (2011) 1.00
Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk. EPMA J (2011) 1.00
Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res (2002) 1.00
Global vasomotor dysfunction and accelerated vascular aging in beta-thalassemia major. Atherosclerosis (2007) 1.00
Oxidative stress markers in laparoscopic versus open colectomy for cancer: a double-blind randomized study. Surg Endosc (2013) 1.00
Early vascular benefits of statin therapy. Curr Med Res Opin (2003) 0.99
Severe hypocholesterolemia with reduced serum lipoprotein(a) in a patient with visceral leishmaniasis. Ann Clin Lab Sci (2002) 0.98
Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J (2006) 0.98
Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin (2004) 0.97
Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C. J Gastroenterol Hepatol (2007) 0.97
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci (2011) 0.96
Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin (2007) 0.96
Influence of smoking on predictors of vascular disease. Angiology (2003) 0.96
Clinical and laboratory characteristics of hypernatraemia in an internal medicine clinic. Nephrol Dial Transplant (2007) 0.96
Evaluation of alternative calculation methods for determining low-density lipoprotein cholesterol in hemodialysis patients. Clin Biochem (2004) 0.94
Plasma lipoproteins and triacylglycerol are predictors of small, dense LDL particles. Lipids (2007) 0.94
The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Atherosclerosis (2005) 0.94
Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. Angiology (2005) 0.93
Benchmarking is associated with improved quality of care in type 2 diabetes: the OPTIMISE randomized, controlled trial. Diabetes Care (2013) 0.93
Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol (2002) 0.93
A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther (2007) 0.92
Pharmacologically-induced metabolic acidosis: a review. Drug Saf (2010) 0.92
Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum (2008) 0.92
Native valve endocarditis due to Micrococcus luteus: a case report and review of the literature. J Med Case Rep (2011) 0.91
High postprandial triglyceridemia in patients with type 2 diabetes and microalbuminuria. J Lipid Res (2006) 0.91
Hyponatremia in patients with infectious diseases. J Infect (2011) 0.91
Disturbances of phosphate metabolism: another feature of metabolic syndrome. Am J Kidney Dis (2005) 0.91
The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids (2006) 0.91
Lipoprotein-associated phospholipase A(2) mass and activity and risk of cardiovascular disease in a population with high prevalences of obesity and diabetes: the Strong Heart Study. Diabetes Care (2012) 0.91
Epitope binning of murine monoclonal antibodies by a multiplexed pairing assay. J Immunol Methods (2011) 0.90
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol (2011) 0.90
Effect of Plant Polyphenols on Adipokine Secretion from Human SGBS Adipocytes. Biochem Res Int (2011) 0.90
Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin (2006) 0.89
Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin (2003) 0.89
The relationship of vitamin D with non-traditional risk factors for cardiovascular disease in subjects with metabolic syndrome. Arch Med Sci (2012) 0.89
Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries. Eur J Prev Cardiol (2012) 0.89
Persistent erythema multiforme in a patient with extrahepatic cholangiocarcinoma. Oncology (2008) 0.89
Association between serum gamma-glutamyltransferase and acute ischemic nonembolic stroke in elderly subjects. Arch Med Res (2009) 0.89